Volume 23, Number 2—February 2017
Dispatch
Determination of Elizabethkingia Diversity by MALDI-TOF Mass Spectrometry and Whole-Genome Sequencing
, Heidi Gumpert, Cecilie Haase Faurholt, and Henrik Westh
Table
Antimicrobial susceptibility of Elizabethkingia isolate HvH-WGS333 from patient with hospital-acquired septic arthritis, Copenhagen, Denmark 2015*
| Antimicrobial | MIC, mg/L | MIC breakpoint, S≤/R>, mg/L | Interpretation |
|---|---|---|---|
| Ciprofloxacin | 0.25 | 0.5/1 | Susceptible |
| Co-trimoxazole | 0.125 | 4/4 | Susceptible |
| Tigecycline | 0.5 | 0.25/0.5 | Intermediate |
| Piperacillin/tazobactam† | 16 | 4/16 | Intermediate |
| Amoxicillin/clavulanic acid‡ | 8 | 2/8 | Intermediate |
| Ampicillin | >256 | 2/8 | Resistant |
| Cefuroxime | >256 | 4/8 | Resistant |
| Ceftazidime | >256 | 4/8 | Resistant |
| Meropenem | >32 | 2/8 | Resistant |
| Gentamicin | 12 | 4/4 | Resistant |
| Colistin | >256 | 4/4 | Resistant |
*Submitted isolate to GenBank (accession no. NZ_MCJF00000000.1). The isolate contains antimicrobial resistance genes blaB-4, blaGOB-13, and an extended-spectrum β-lactamase, sharing 90.6% nucleotide identity to blaCME-1. Antimicrobial susceptibility testing was performed by using Etest (bioMérieux, Marcy l’Etoile, France) according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (http://www.eucast.org). For interpretation, non–species-related (pharmacokinetics/pharmacodynamics) breakpoints were used except for co-trimoxazole, in which Stenotrophomonas malthophilia breakpoints were used, and for gentamicin and colistin, in which Pseudomonas sp. breakpoints were used. R, resistance; S, susceptibility.
†For susceptibility testing purposes, the concentration of tazobactam was fixed at 4 mg/L.
‡For susceptibility testing purposes, the concentration of clavulanic acid was fixed at 2 mg/L.